Use of interleukin-1 beta mutein conjugates in the treatment of diabetes

Details for Australian Patent Application No. 2010294249 (hide)

Owner Cytos Biotechnology AG

Inventors Bachmann, Martin; Spohn, Gunther; Maurer, Patrik

Agent Watermark

Pub. Number AU-A-2010294249

PCT Pub. Number WO2011/029870

Priority 09169989.2 10.09.09 EP

Filing date 9 September 2010

Wipo publication date 17 March 2011

International Classifications

C07K 14/545 (2006.01) Peptides having more than 20 amino acids

A61K 38/20 (2006.01) Medicinal preparations containing peptides - Interleukins

A61K 39/385 (2006.01) Medicinal preparations containing antigens or antibodies - Haptens or antigens, bound to carriers

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

Event Publications

3 May 2012 PCT application entered the National Phase

  PCT publication WO2011/029870 Priority application(s): WO2011/029870

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010294252-New foamed tea beverage and process of preparation

2010294248-Hypoallergenic hybrid polypeptides for the treatment of allergy